CASI Pharmaceuticals, Inc. · OTC:CASIF
CASI Pharmaceuticals — Investor Presentation (September 2019)
13 slides from CASI Pharmaceuticals's investor presentation, September 2019
Slide 1: Corporate Presentation September 9-10, 2019
Corporate Presentation September 9 - 10, 2019 1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to
Slide 3: EVOMELA Launched in China
EVOMELA ® Launched in China • Only approved melphalan product in China market • HDT+ASCT is 1st line treatment for multiple myeloma even in new agent era • Provides best choice of preparative regimen • Lack of propylene glycol solvent (related to certain adverse events) • Stable and significantly im
Slide 4: CASI Pipeline
CASI Pipeline In addition, to address the high demand by patients in China for high-quality, affordable pharmaceuticals, CASI has acquired a portfolio of U.S. FDA approved and pending ANDAs for generic products. 4
Slide 5: Recent Execution in Hematology Oncology Portfolio
Recent Execution in Hematology Oncology Portfolio Launched in China for multiple myeloma transplant setting in August 2019 Acquired worldwide rights to commercialize anti-CD19 CNCT-19, anti-CD19 T-Cell Therapy T-cell therapy in June 2019 – targeting acute lymphoblastic leukemia and non-hodgkin’s lym
Slide 6: CNCT-19 (Anti-CD19 T-Cell Therapy)
CNCT-19 (Anti-CD19 T-Cell Therapy) • Targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and validated target for B-cell derived hematological malignancies • CD19-targeted CAR have demonstrated consistently high antitumor efficacy in children and adults wi
Slide 7: CID-103 (Potential Best in Class Anti-CD38 mAb)
CID-103 (Potential Best in Class Anti-CD38 mAb) • Fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope; engineered to have strong ADCC activity against CD38 malignant cells and to reduce CDC activity with a potential reduction of infusion reactions with observed with existing
Slide 8: ZEVALIN and MARQIBO Clinical Trial Application Approval in China
ZEVALIN® and MARQIBO® Clinical Trial Application Approval in China ⚫ CD20-directed radiotherapeutic antibody indicated for treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (FNHL) and patients with previously untreated follicular non-Hodgkin’s L
Slide 9: Global Executive Team
Global Executive Team • Vice President of • 23 years of • 25 years of Novartis (China) experience in experience in global drug biotech investment • CEO of Sandoz development Pharmaceuticals • Founder of (China) • CEO & CMO of Emerging Arno Therapeutics Technology • Leadership roles at Partners, LLC
Slide 10: Commercial Team for Launch of EVOMELA
Commercial Team for Launch of EVOMELA® • 21 managerial and upper employees in commercial organization, all with more Heilongjiang than 10 years experiences at large international pharmaceutical companies IM Jilin Liaoning Xinjiang BJ • 90% of employees in commercial TJ operations have prior experien
Slide 11: R&D and Manufacturing Center in Wuxi
R&D and Manufacturing Center in Wuxi • State-of-art GMP facility currently in design and planning stage • Approximately 17.6 acres of land located in major biotech and pharmaceutical region • Over 100,000 square meters of building area • Convenient transportation to 2 airports, high speed train stat
Slide 12: CASI Key Highlights
CASI Key Highlights • Launched EVOMELA® (melphalan for injection), the only commercially available melphalan in China • Robust pipeline in hematology oncology • CID-103 (potential best in class anti-CD38 mAb) • CNCT-19 (anti-CD19 T-Cell Therapy) • ZEVALIN ® • MARQIBO® • Led by an international execu
Slide 13: THANK YOU
THANK YOU NASDAQ: CASI www.casipharmaceuticals.com 13
CASI Pharmaceuticals — Investor Presentation (September 2019) on 6ix